0001209191-23-005044.txt : 20230126 0001209191-23-005044.hdr.sgml : 20230126 20230126160832 ACCESSION NUMBER: 0001209191-23-005044 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230124 FILED AS OF DATE: 20230126 DATE AS OF CHANGE: 20230126 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Galimi Francesco CENTRAL INDEX KEY: 0001823996 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38359 FILM NUMBER: 23557762 MAIL ADDRESS: STREET 1: 12930 VIA ESPERIA CITY: DEL MAR STATE: CA ZIP: 92014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adicet Bio, Inc. CENTRAL INDEX KEY: 0001720580 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 813305277 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: 617-482-2333 MAIL ADDRESS: STREET 1: 200 BERKELEY STREET STREET 2: 19TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: resTORbio, Inc. DATE OF NAME CHANGE: 20171024 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-01-24 0 0001720580 Adicet Bio, Inc. ACET 0001823996 Galimi Francesco C/O ADICET BIO, INC. 200 BERKELEY STREET, 19TH FLOOR BOSTON MA 02116 0 1 0 0 SVP & Chief Medical Officer Common Stock 2023-01-24 4 A 0 26100 0.00 A 88551 D Stock Option (Right to Buy) 9.05 2023-01-24 4 A 0 117200 0.00 A 2033-01-23 Common Stock 117200 117200 D The Reporting Person was issued Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock. The RSUs shall vest in three (3) annual installments, with the first tranche vesting on January 24, 2024. The RSUs may be settled only by delivering shares of Common Stock, and thus, the grant is being reported in Table I as allowed per SEC guidance. 1/48th of the shares shall vest on each of the next forty-eight (48) monthly anniversaries of the grant date, provided that the Reporting Person maintains a service relationship with the Company as of the applicable vesting dates. /s/ Nick Harvey, Attorney-in-Fact 2023-01-26